Search GHK-Cu side effects and you get lists of mild skin complaints. Those lists come from cosmetic cream studies that ran about 12 weeks. The injected form has zero published human trials, so it has no side effect record to list.
The short answer. Reported GHK-Cu side effects are skin side effects, from cosmetic cream studies lasting about 12 weeks.
- Copper contact allergy is the one clearly documented mechanism for a reaction to topical use.
- Injectable GHK-Cu has zero published human trials, so it has no measured safety profile at all.
- No published human study has tracked serum copper, liver or kidney markers after GHK-Cu injection.
Topical GHK-Cu rests on roughly 30 controlled studies. Most reported problems there were skin problems. Redness, itching and stinging at the application site. Copper allergy is a known cause of contact dermatitis. Injectable GHK-Cu has zero published human trials. So its side effect profile is unmeasured, not clean.
What side effects have actually been reported?
The reported ones are skin reactions. That is because the human research is skin research.
The most cited controlled work is the 2002 study by Leyden and colleagues, presented at the American Academy of Dermatology meeting. It tested a copper peptide facial cream in 71 women with sun-damaged skin over 12 weeks. Creams in that class are generally described as well tolerated.
Here is the catch. A cosmetic efficacy study is not a safety trial. It counts wrinkles and skin roughness. It is not powered to find a rare adverse event, and it does not follow anyone for years.
- Local irritation. Stinging, burning or redness where the product was applied.
- Itching and dryness. Common with any active leave-on cosmetic base.
- Contact allergy to copper. Copper is a recognized contact sensitizer in a small share of people.
- Interaction with other actives. Layering with strong acids or retinoids raises irritation risk on the same skin.
Our before and after page covers what those same trials measured on the efficacy side.
Injectable GHK-Cu side effects: the record is empty
This is the part the side effect lists skip. The lists were built from cream studies, then copied onto a vial.
There is no published human trial of injected GHK-Cu. No efficacy study, no safety study, no pharmacokinetics. An empty record is not a good record. It is an unread one.
A 2026 review in Sports Medicine looked at peptides sold for musculoskeletal injury and athletic performance. Its finding for this whole category was that rigorous human safety data is scarce.
Rigorous human safety and efficacy data are scarce for most of these peptides, and many are marketed for uses that no controlled clinical trial supports.
Mendias & Awan, Sports Medicine, 2026So the honest answer for the injected route is short. Nobody has measured what it does. See injectable versus topical for the full split, and the dosage page for why no injectable dose exists to report.
Does GHK-Cu cause copper toxicity?
Nobody has published the measurement that would answer this in people.
GHK-Cu is a three-amino-acid peptide carrying one copper(II) ion. The copper is the point. It is what lets the molecule act as a cofactor source for lysyl oxidase, the enzyme that cross-links new collagen. The mechanism page walks through that chain.
Copper is also a metal the body regulates tightly. Overload is a real clinical entity. That is why the missing data matters more here than it would for a peptide with no metal attached.
What is missing, specifically:
- No serum copper follow-up. We found no published human study that measured copper levels after GHK-Cu injection.
- No liver or kidney panels. Those are the organs that handle copper, and no trial has reported them for this compound.
- No long-term skin study. The controlled cosmetic work runs weeks, not years.
- No data in copper metabolism disorders. Wilson disease and similar conditions have never been studied with this peptide.
Topical delivery is a partly separate question, because most of the molecule does not get through. A 2023 paper in Pharmaceutics and a 2025 paper in Molecules both examined GHK skin permeability. At about 340 Da the free peptide is small, but the charged copper complex crosses the stratum corneum poorly, which is why formulators keep building delivery systems for it.
GHK-Cu
The compound discussed here, supplied as a research compound with a certificate of analysis matched to the lot.
What the animal studies used it for, and what they did not test
The recent preclinical literature is busy, and it is almost all efficacy work in disease models. Safety endpoints are secondary in those papers.
| Study | Model | What it was testing |
|---|---|---|
| Bian et al., Redox Biology, 2024 | Silicosis lung injury | Reduced inflammation and fibrosis via peroxiredoxin 6 |
| Mao et al., Frontiers in Pharmacology, 2025 | Ulcerative colitis | SIRT1/STAT3 signaling |
| Chen et al., Biomaterials Research, 2025 | Infected wounds | Tripeptide-copper self-healing hydrogel |
| Lee et al., Acta Biomaterialia, 2023 | Wound healing | Hyaluronic acid hydrogel with GHK nanofibers |
None of those is a human safety study. Animal models are where a toxicology signal often shows first, and these papers are encouraging on that front. They still cannot tell a person what a vial will do to them. The wound healing page covers the hydrogel work in detail.
Why the peptide is often called safe
Because it is already in you. That argument is real, and it is also incomplete.
GHK was identified in 1973 at UC San Francisco as a fragment present in human plasma. Levels decline with age. Dou and colleagues, writing in Aging Pathobiology and Therapeutics in 2020, describe the drop directly.
Plasma GHK is about 200 ng/mL at age 20 and falls to roughly 80 ng/mL by age 60.
Dou et al., Aging Pathobiology and Therapeutics, 2020So a ~60% between age 20 and 60 decline is the reason people call it a restoration rather than a drug. Fair enough. But an endogenous molecule at physiological blood levels is not the same as an injected bolus of a copper complex from a research vial. Insulin is endogenous too.
The other half of the argument is time. Topical copper peptide has been in cosmetics since the 1990s, roughly 50 years after discovery, with no signal of a serious widespread problem. That is meaningful for creams. It says nothing about needles.
Who has the most reason to be cautious
This is not medical advice, and the list below is not a screening tool. It is where the published record is thinnest.
People with a known copper or nickel contact allergy have a documented reason for concern with topical use. People with a copper metabolism disorder have no data at all, in either route. Pregnancy and breastfeeding have never been studied with this compound. Neither has use on broken or freshly wounded skin outside of the hydrogel research settings.
Product quality is its own safety variable. A copper peptide vial can be mislabeled, underdosed or contaminated, and none of that shows up in a study of the molecule. Read the certificate of analysis guide and the storage page before assuming what is in the bottle.
For background on the compound itself, the complete guide collects the source studies for both routes.
GHK-Cu
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- Reported GHK-Cu side effects are skin side effects, from cosmetic cream studies lasting about 12 weeks.
- Copper contact allergy is the one clearly documented mechanism for a reaction to topical use.
- Injectable GHK-Cu has zero published human trials, so it has no measured safety profile at all.
- No published human study has tracked serum copper, liver or kidney markers after GHK-Cu injection.
- A 2026 Sports Medicine review found rigorous human safety data scarce across this whole peptide category.
- Endogenous plasma GHK at 200 ng/mL is not the same exposure as an injected copper complex.
What we're watching
The thing to watch for is a published human trial of injected GHK-Cu that reports serum copper alongside liver and kidney markers. Until one exists, the injectable safety record stays empty rather than clean.
Frequently asked questions
Can GHK-Cu cause skin irritation?
Yes, that is the most commonly described issue. Cosmetic studies of copper peptide creams report local effects like stinging, redness, itching or dryness. Copper is also a recognized contact allergen for a small number of people. These trials were efficacy studies, not safety trials, so they were not designed to catch rare reactions.
Is injectable GHK-Cu safe?
Nobody knows, because nobody has published the study. There are zero published human trials of injected GHK-Cu, in any indication. That means no adverse event tables, no pharmacokinetics and no dosing data exist for that route. A 2026 review in Sports Medicine described rigorous human safety data as scarce for peptides sold this way.
Can GHK-Cu cause copper toxicity?
No published human study has measured it. GHK-Cu carries one copper(II) ion, and copper overload is a real clinical condition. We found no trial that tracked serum copper, liver function or kidney function after GHK-Cu use in people. That is an unanswered question rather than a reassurance.
How long did the human safety studies run?
About 12 weeks. The controlled topical work, including the 2002 Leyden facial cream study in 71 women with sun-damaged skin, ran on cosmetic timelines. There is no published multi-year follow-up for GHK-Cu in any route.
Does GHK-Cu cause hair shedding?
No controlled human study has reported that. The hair research is small and uncontrolled, mostly cell work in dermal papilla cells and small graft survival reports. Our hair follicle page covers what those studies did and did not measure.
Are there known drug interactions with GHK-Cu?
None have been published. There are no human interaction studies for this compound. On skin, the practical issue reported in cosmetic literature is stacking irritants: combining a copper peptide with strong acids or retinoids raises the chance of local irritation.
References
- Mendias, C. L., & Awan, T. M. (2026). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Medicine. https://doi.org/10.1007/s40279-026-02437-0
- Dou, Y., Lee, A., Zhu, L., et al. (2020). The potential of GHK as an anti-aging peptide. Aging Pathobiology and Therapeutics, 2(1), 58–61. https://doi.org/10.31491/apt.2020.03.014
- Mao, J., Wei, S., Pang, Z., et al. (2025). GHK-Cu attenuates ulcerative colitis through the SIRT1/STAT3 signaling pathway. Frontiers in Pharmacology, 16, 1551843. https://doi.org/10.3389/fphar.2025.1551843
- Lee, M., Kim, B., Kim, S., et al. (2023). Photo-crosslinkable hyaluronic acid hydrogel with GHK peptide nanofibers for wound healing. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2023.10.011
- Dymek, M., Warszyński, P., & Sikora, E. (2023). GHK Peptide Permeability and Its Effects in Anti-Aging Skincare Topical Formulations. Pharmaceutics, 15(10), 2485. https://doi.org/10.3390/pharmaceutics15102485
- Ogórek, P., Gostińska, K., Wahab, S., et al. (2025). GHK-Cu in cosmetic applications: skin permeation and delivery strategies. Molecules, 30(1), 136. https://doi.org/10.3390/molecules30010136
- Chen, H., Yang, P., Xue, P., et al. (2025). Food-derived tripeptide-copper self-healing hydrogel for infected wound healing. Biomaterials Research, 29, 0139. https://doi.org/10.34133/bmr.0139
- Bian, Y., Deng, M., Liu, J., et al. (2024). The glycyl-l-histidyl-l-lysine-Cu tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6. Redox Biology, 75, 103237. https://doi.org/10.1016/j.redox.2024.103237
- Leyden, J. J., Stephens, T. J., Finkey, M. B., et al. (2002). Skin care benefits of copper peptide containing facial cream. American Academy of Dermatology Annual Meeting Poster Abstract. PubMed search PMID ?term=Leyden+copper+peptide+facial+cream+2002